Urolithin A: what dose, for how long, and what the trial actually measured
· by VEXTA Team
How much per day?
The reference trial for urolithin A is Singh 2022 (Cell Reports Medicine, DOI 10.1016/j.xcrm.2022.100633, registered as NCT03464500): randomised, placebo-controlled, in middle-aged adults, with two doses administered over four months — 500 mg and 1,000 mg per day.
Both doses produced measurable effects. The 500 mg daily dose is the one most formulations adopt, including ours: it is the lower of the two studied levels to show a signal, which makes it the rational starting point.
What the trial measured — and what it did not
This trial deserves to be quoted in full, including what failed. The published results:
- Muscle strength: roughly +12% versus placebo, significant
- Improvements judged clinically meaningful in aerobic endurance (peak VO₂) and physical performance (six-minute walk test)
- No significant improvement in the study's primary endpoint, peak power output
- Plasma acylcarnitines and C-reactive protein significantly lower
- Significant increase in the expression of mitophagy-related proteins in skeletal muscle
A trial that misses its primary endpoint is still a trial whose secondary endpoints are informative — but it cannot be presented as a complete demonstration. That is the honest reading of the available literature.
How long is a course?
Four months. That is the trial duration, and the window over which effects were observed. The four- to six-week protocols frequently seen online correspond to no published trial on this molecule.
If you are evaluating urolithin A, set a 16-week window and decide in advance what you will observe — a load on a given exercise, a distance, a recovery time. A general impression over a fortnight will tell you nothing usable.
Why supplementation exists at all: the metabotype question
Urolithin A is not present as such in food. It is produced by the gut microbiota from the ellagitannins in pomegranate, walnuts and berries. That conversion depends on microbiota composition: Tomás-Barberán 2014 (Journal of Agricultural and Food Chemistry, DOI 10.1021/jf5024615) describes distinct metabotypes — not everyone produces the same urolithins from the same dietary intake.
That is the rationale for direct supplementation: it bypasses the microbial step and makes intake independent of gut profile.
Timing and tolerability
Trials use a single daily dose without comparing schedules. No data supports recommending mornings over evenings. As with any long course, the timing that matters is the one you will keep for four months.
Available tolerability data covers middle-aged adults over four months. It covers neither pregnancy, nor breastfeeding, nor drug interactions. Medical advice is recommended if you are on treatment.